Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable resistance from pharmacy benefit managers. The companies are https://aoifemchj542005.vblogetin.com/48140740/company-s-drug-faces-is-encountering-managed-care-organization-hurdles-the-look-of-reimbursement-disputes